DUBLIN–(BUSINESS WIRE)–The “Oncolytic Virus Cancer Therapy – Pipeline Insight, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This Oncolytic Virus Cancer Therapy – Pipeline Insight, 2021 report provides comprehensive insights about 45+ companies and 85+ pipeline drugs in Oncolytic Virus Cancer Therapy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Oncolytic Virus Cancer Therapy R&D. The therapies under development are focused on novel approaches for Oncolytic Virus Cancer Therapy.
Oncolytic Virus Cancer Therapy Emerging Drugs Chapters
This segment of the Oncolytic Virus Cancer Therapy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Oncolytic Virus Cancer Therapy Emerging Drugs
CG0070: CG Oncology
CG0070 is an investigational oncolytic immunotherapy based on a modified common cold adenovirus backbone that contains a cancer-specific promoter and a GM-CSF transgene. CG0070, first replicates inside the tumor’s cells causing tumor cell lysis and immunogenic cell death.
Then, the rupture of the cancer cells can release tumor-derived antigens, along with GM-CSF, that can stimulate a systemic anti-tumor immune response that involves the body’s own white blood cells. CG0070 is in development for a variety of solid tumor types to be used alone or in combination with immune checkpoint modulators.
The therapy is in clinical development for the treatment of Bladder cancer and preclinical studies for solid tumors. In advanced clinical studies, CG0070 has been shown to be a safe and efficacious agent in NMIBC following BCG failure.
ONCOS-102: Targovax
ONCOS-102 is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system to fight the cancer. ONCOS-102 is currently being tested in mesothelioma, melanoma and peritoneal malignancies and has shown promising clinical results both as monotherapy and in combination with chemotherapy, and a checkpoint inhibitor.
In February 2021, Targovax announced that ONCOS-102 has received Fast-Track designation in malignant pleural mesothelioma from the US FDA.
Oncolytic Virus Cancer Therapy: Therapeutic Assessment
Major Players working on Oncolytic Virus Cancer Therapy
There are approx. 45+ key companies which are developing the Oncolytic Virus Cancer Therapy. The companies which have their Oncolytic Virus Cancer Therapy drug candidates in the most advanced stage, i.e. Phase III include, CG Oncology.
Phases
This report covers around 85+ products under different phases of clinical development like
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Oncolytic Virus Cancer Therapy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
Products have been categorized under various Molecule types such as
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Oncolytic Virus Cancer Therapy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Oncolytic Virus Cancer Therapy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Oncolytic Virus Cancer Therapy drugs.
Oncolytic Virus Cancer Therapy Report Insights
- Oncolytic Virus Cancer Therapy Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Oncolytic Virus Cancer Therapy Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Scenario and Emerging Therapies:
- How many companies are developing Oncolytic Virus Cancer Therapy drugs?
- How many Oncolytic Virus Cancer Therapy drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Oncolytic Virus Cancer Therapy?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Oncolytic Virus Cancer Therapy therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Oncolytic Virus Cancer Therapy and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- CG Oncology
- Oncolytics Biotech
- Astellas Pharma
- DNAtrix
- Nouscom
- ImmVira Pharma
- Targovax
- Istari Oncology
- SillaJen Biotherapeutics
- Transgene
- Advantagene
- Wuhan Binhui Biotechnology
- PsiOxus Therapeutics
- VCN Biosciences
- Vyriad
- Oncolys Biopharma
- Replimune
- Oncorus
Key Products
- CG0070
- Pelareorep
- ASP-9801
- DNX 2440
- NOUS PEV
- T3011
- ONCOS-102
- PVS-RIPO
- Pexa-Vec
Research Programme:
- rQNestin 34.5
- oHSV-2
- Enadenotucirev
- NG-348
- NG-350A
- NG-641
- NG-347
- NG-796A
- VCN-01
- Voyager-V1
- TG6002
- BT 001
- Tasadenoturev
- Suratadenoturev
- RP1
- OBP-702
- ONCR-177
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/8mqnq0
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900